Indoco Remedies (NSE:INDOCO) filed an intimation with NSE and BSE on 21st August 2026, confirming Thursday, 10th September 2026 as the record date for determining shareholder eligibility for a final dividend of Rs 0.20 per equity share for the financial year ended 31st March 2026.
Key Highlights
- The board of directors recommended a final dividend of Rs 0.20 per equity share for FY2026, subject to shareholder approval at the 79th AGM on 17th September 2026.
- Thursday, 10th September 2026 has been fixed as the record date for determining entitlement to the final dividend under SEBI Listing Obligations Regulation 42.
- The Register of Members and Share Transfer Books will remain closed from Friday, 11th September 2026 to Thursday, 17th September 2026, both days inclusive.
- The cut-off date for remote e-voting and AGM e-voting is also fixed as 10th September 2026, covering shareholders in both physical and dematerialised form.
About the Company
Indoco Remedies Limited (NSE:INDOCO), headquartered in Mumbai, is a fully integrated pharmaceutical company engaged in the manufacture and marketing of formulations and active pharmaceutical ingredients. The company operates multiple manufacturing facilities in India and exports its products to regulated markets including the United States, Europe, and other international geographies. It is listed on both NSE and BSE under stock codes INDOCO and 532612 respectively.
Announcement in Detail
The filing, submitted on 21st August 2026 and signed by Company Secretary and Head-Legal Ramanathan Hariharan, references the earlier board intimation of 7th May 2026 in which the board recommended a final dividend of Rs 0.20 per equity share for the financial year ended 31st March 2026. This recommendation remains conditional upon shareholder approval at the 79th Annual General Meeting scheduled for 17th September 2026.
Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has established 10th September 2026 as both the record date for dividend entitlement and the cut-off date for e-voting eligibility. If approved at the AGM, dividend payment, after applicable tax deduction at source, will be made within 30 days of such approval.
Impact on Investors
Investors will note that only shareholders holding shares as of the record date of 10th September 2026, whether in physical or dematerialised form, will be eligible for the declared dividend of Rs 0.20 per equity share. The filing shows that the dividend remains a recommendation and has not yet been formally approved; shareholders will need to vote in favour at the 79th AGM on 17th September 2026 for the payment to proceed.
The disclosed terms indicate that dividend payment will be made within 30 days of AGM approval, subject to deduction of tax at source as applicable. Shareholders will also observe that the book closure period from 11th to 17th September 2026 restricts share transfers during those dates for dividend eligibility purposes.
Sector / Market Context
India's pharmaceutical industry is among the largest globally by volume, with the domestic formulations market continuing to grow on the back of rising healthcare spending and government initiatives such as the Production Linked Incentive scheme for pharmaceuticals. Dividend distributions by listed pharma companies are monitored closely by institutional investors as indicators of balance sheet strength, and SEBI's standardised record-date framework under Regulation 42 ensures uniform disclosure timelines across all listed entities in the sector.